Clinical & Experimental Cardiology
Open Access

The Promises of Pulmonary Pulsatility-Should we Leave in Forward Flow in the Fontan Operation?

Robert Michael Rhys Tulloh Professor^1* and Kritika Kalia^{2 *}Correspondence: Robert Michael Rhys Tulloh, Professor, Department of Congenital Heart Disease, University Hospitals Bristol and Weston NHS Foundation Trust, Upper Maudlin Street, Bristol, United Kingdom,

Author info »

Background

The Fontan operation represents a well-traversed surgical pathway for children with functionally Univentricular Hearts (fUVH) [1]. In an initial study assessing long-term outcomes, Francis Fontan quoted a 20-year survival of 65% in the best surgical candidates. However, adoption of contemporary surgical techniques has transformed the outlook of fUVH defects, with current 20-year survival rates range between 80%-90% [2,3], far exceeding Fontan’s initial prediction. Yet, despite incremental improvement in survival and impressive late functional outcomes, the contemporary Fontan remains far from the ideal solution for complex congenital heart disease.

Fundamentally, the Fontan circulation subjects the patient to a highly abnormal cardiopulmonary physiology. As the population of adult Fontan survivors grows, the pernicious effects of these haemodynamics become increasingly pronounced, with one pertinent study reporting a statistically significant decline in freedom from late adverse events with prolonged duration of follow-up [4]. It is clear that novel strategies are essential to minimise the inherent inefficiencies of a Total Cavo-Pulmonary Connection (TCPC) and overcome this almost expected gradual attrition: the ‘failing Fontan’ due to the Fontan paradox with associated complications of liver fibrosis, renal dysfunction and eventual cardio-pulmonary failure [5,6](Figure 1).

Figure 1: Late clinical complications following the Fontan operation. Fontan ‘failure’ may present with a myriad of clinical manifestations, including various cardiac and extracardiac sequelae which contribute to the excess late morbidity and mortality seen in adult survivors. Abbreviations: AVM: Arteriovenous Malformation; ET: Exercise Tolerance; HCC: HepatoCellular Carcinoma; HTN: Hypertension.

The role of maintaining Anterograde Pulmonary Blood Flow (APBF) during Fontan palliation has been garnering significant interest. With exclusion of right ventricular hydraulic energy, adequate cardiac output in the completed Fontan circuit, or TCPC, is contingent on low Pulmonary Vascular Resistance (PVR). Crucially, chronic privation of pulsatile pulmonary flow may be detrimental for endothelial function, capillary recruitment and pulmonary vascular development, all of which adversely impact PVR, as evidenced in animal models [7,8].

This premise has been corroborated in recent clinical studies; Chen, et al. [9] have shown favourable effects on haemodynamic proxies of endothelial function in patients with additional pulmonary blood flow, namely greater flow pulsation and region velocity, and, importantly, increased wall shear stress. Similarly, Ferns, et al. [10] have demonstrated important trophic effects (Nakata index) of residual pulsatile anterograde flow after BidirectionalGlenn (BDG), which persist long after Fontan completion.

We have also previously reported on the utility of preserving APBF after BDG [11]. However, there appears to be a scarcity of studies which correlate these findings with clinical outcome data. To this effect, our present study aimed to evaluate whether maintenance of APBF at the time of Fontan was associated with improved haemodynamic outcomes [12].Review of Literature

Review of Literature

Study findings

Our cohort included 106 children who underwent Fontan completion at University Hospitals Bristol NHS Foundation Trust between1999 2018. 39 patients (36.8%) had APBF at the time of Fontan. Using routine preoperative cardiac catheterisation data, we calculated a novel pulmonary artery Pulsatility Index (PI) for each subject: PI=(pulmonary artery systolic pressure−pulmonary artery diastolic pressure)/mean pulmonary artery pressure. This formula was adapted from the doppler-derived blood velocity equation, which is commonplace in obstetric [13] and stroke medicine [14]. The study population was subsequently divided into thirds, according to PI magnitude, enabling both spectral and sub-group analysis. As expected, those with residual APBF have a significantly higher pulsatility index (Mann-Whitney U, p<0.0001).

There were no significant differences in early standard cardiac surgical outcomes, namely early mortality, post-operative ventilatory time and chest drainage time, duration of Paediatric Intensive Care Unit (PICU) and total hospital stay, or Systemic Arterial Oxygen Saturation (SaO₂) at discharge, based upon pulsatility index.

Late outcome measures included change in ventricular function and atrioventricular valve regurgitation (echocardiography), exercise tolerance (Ross/NYHA), SaO₂ at 1-year and last follow- up, medication support (diuretics and vasodilatory therapy) and intermediate (within one year) or late (after one year) Fontan failure. Whilst there was no statistically significant difference in long-term outcomes according to PI, there was a trend towards improved ventricular function in the medium PI sub-group (Kruskal-Wallis, p=0.0723). Similarly, there was a tendency towards higher SaO₂ with increasing Pulsatility (Figure 2), but this did not each statistical significance on either spectral or subgroup analysis.

Figure 2: Trends in long-term systemic arterial oxygen saturation. The left-hand side depicts spectral analysis of SaO2 at (a) 1-year and (c) at last follow-up. The calculated Pearson R and associated p-value is shown. Data points in light blue indicate subjects with ‘low PI,’ with medium blue and dark blue representing those with ‘medium PI’ and ‘high PI’ respectively. On the right-hand sie, results from subgroup analysis are graphed, at (b) 1-year and (d) last follow-up, with associated p values (Kruskal–Wallis).

All patients in the high PI subgroup maintained SaO₂ ≥ 90% at 1-year and last follow-up.

Discussion

Our present study adds to an accruing body of literature attempting to delineate whether the proposed benefit of pulsatile pulmonary perfusion in the Fontan population translates from bench to bedside. Although auxiliary pulsatile APBF did not impact short- term outcomes or long-term prognosis in our cohort, there was a tendency toward improved postoperative SaO₂, which may have lasting clinical benefits not identified within the time frame of our study. of note, all subjects in the ‘high PI’ subgroup maintained SaO₂ ≥ 90% at both 1-year and last follow-up. Given that the chronic hypoxic environment prior to Fontan completion has previously been implicated as a contributor to the aberrant vascular function in this population [15], residual APBF may hold additional benefit in patients with lower pre-operative SaO₂, including those with suboptimal preoperative pulmonary physiology as evidenced by higher PVR. Our present study was not designed to specifically evaluate this. We postulate that a further study is merited to investigate this relationship and answer these difficult questions.

There is a sound experimental evidence-base for preserving pulsatile pulmonary flow. On a molecular level, pulsatile shear stress upregulates endothelial Nitric Oxide Synthase (eNOS) and, through nitric oxide-mediated vasodilation, promotes vascular compliance [16,17]. This premise has been replicated in animal studies, including a chronic porcine model of BDG [18]. Here, micro-pulsatility (achieved by partial ligation of the pulmonary artery) aligned with significantly lower PVR, compared with total absence of pulsatility (complete pulmonary artery ligation).

Whilst these findings are compelling, the clinical decision whether to maintain or exclude APBF is more divisive. Proponents advocate that pulsatile perfusion during staging may be an underemployed strategy to protect and optimise the pulmonary vasculature: given the passive nature of cavo-pulmonary flow, even marginal increases in PVR can have profound consequences in the Fontan patient, with worsening preload deprivation and circulatory output [19]. However, opponents remain concerned that accessory pulmonary flow contributes to excessive ventricular volume loading, thereby mitigating some of the advantageous effect of the BDG [20]. It is evident that further research is required to elucidate whether there is an optimal level of auxiliary anterograde flow to retain adequate pulsatility to nurture the endothelium, without significantly loading the single ventricle. With the capacity to facilitate more robust pulmonary pulsatility quantification and more accurate ventricular and atrioventricular valve functional assessment, we posit that Cardiac MRI (CMR) may be a powerful tool for evaluating these parameters in future related studies.

The distinction between ‘pulsatile’ and ‘non-pulsatile’ flow is more ambiguous in human subjects as compared with animal models, adding a further layer of complexity. Although pulmonary artery banding should leave ‘pulsatile’ flow, where banding restricts the outflow tract to subcritical levels, this might closely emulate laminar blood flow. Equally, in the setting of systemic-to-pulmonary artery shunt, or aortopulmonary collateralisation, haemodynamic may be salutary and possess a pulsatile character, more closely replicating the arterial, as compared with a venous, waveform. From this, it is clear that novel non-invasive modalities to assess pulsatility could have great utility in investigating the translation of pulsatile perfusion to clinical practice, and ultimately help optimise clinical decision making in the palliation process.

Conclusion

Management of the failing Fontan represents a major clinical challenge. This review seeks to encourage clinicians to take a more proactive role during the initial staging steps, to identify children who may benefit from such optimisation approaches, rather than focusing solely on strategies which react to the failing circuit.

The idealistic approach going forward would be a recommendation for randomised controlled trials comparing pulsatile APBF versus total exclusion of additional pulmonary flow. This would ultimately provide robust end-point clinical data to justify one surgical strategy over the other. However, this is an immense oversimplification; first, given the heterogeneity of complex congenital heart disease, a ‘one-size-fits all’ approach is unlikely to yield success. Secondly, it is a fundamental prerequisite of clinical practice to closely consider the risks and benefits of any proposed action on a case-by-case basis, and to communicate this clearly to the patient and family to inform consent. As such, the ethical implications of randomisation to surgery in a paediatric population would at best be contentious, especially when considering that patients with certain fUVH pathologies would predictably respond poorly to a particular approach, aligning with poor outcomes. Thus, randomised controlled trials are highly unlikely in this arena.

From the recent study by Chen, et al. which employed computational fluid dynamic simulation, the benefits of APBF appear to be contingent on numerous measurable haemodynamic parameters. Whilst APBF was shown to be accompanied by an improvement in indexed energy loss and systemic arterial saturation, it also adversely impacted pressure in the right superior vena cava and subsequently increased heart load. With such technological advancements, it may become habitual and commonplace to measure these indices in clinical practice. Analysis of these parameters in large subgroups of fUVH patients, and correlating them with clinical outcome over longer time frames, may facilitate identification of specific defects which may respond more favourably to maintaining APBF. As such, we propose that efforts directed at national, and, preferably, international collaborations to formulate large datasets of haemodynamic data could be fruitful. This would ultimately enable creation of robust risk-stratification algorithms and pave the way for a future which promotes a personalised management approach.

References

1. Fontan F, Kirklin JW, Fernandez G, Costa F, Naftel DC, Tritto F, et al. Outcome after a "perfect" Fontan operation. Circulation. 1990; 81: 1520-1536.
2. d'Udekem Y, Iyengar AJ, Cochrane AD, Grigg LE, Ramsay JM, Wheaton GR, et al. The Fontan procedure: Contemporary techniques have improved long-term outcomes. Circulation. 2007; 116: I157-I164.
3. Dabal RJ, Kirklin JK, Kukreja M, Brown RN, Cleveland DC, Eddins MC, et al. The modern Fontan operation shows no increase in mortality out to 20 years: A new paradigm. J Thorac Cardiovasc Surg. 2014; 148: 2517-2523.e1.
4. d'Udekem Y, Iyengar AJ, Galati JC, Forsdick V, Weintraub RG, Wheaton GR, et al. Redefining expectations of long-term survival after the Fontan procedure: Twenty-five years of follow-up from the entire population of Australia and New Zealand. Circulation. 2014; 130: S32-S38.
5. Rychik J, Goldberg D, Rand E, Semeao E, Russo P, Dori Y, et al. End-organ consequences of the Fontan operation: Liver fibrosis, protein-losing enteropathy and plastic bronchitis. Cardiol Young. 2013; 23: 831-840.
6. Rychik J. The Relentless effects of the fontan paradox. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2016; 19: 37-43.
7. Mandelbaum I, Burns WH. Pulsatile and nonpulsatile blood flow. JAMA. 1965; 191: 657-660.
8. Raj JU, Kaapa P, Anderson J. Effect of pulsatile flow on microvascular resistance in adult rabbit lungs. J Appl Physiol. 1992; 72: 73-81.
9. Chen X, Yuan H, Liu J, Zhang N, Zhou C, Huang M, et al. Hemodynamic effects of additional pulmonary blood flow on glenn and fontan circulation. Cardiovasc Eng Technol. 2020; 11: 268-282.
10. Ferns SJ, Zein CE, Subramanian S, Husayni T, Ilbawi MN. Post-Fontan pulmonary artery growth in patients with a bidirectional cavopulmonary shunt with additional antegrade pulsatile blood flow. Asian Cardiovasc Thorac Ann. 2020; 218492320984095.
11. Chen Q, Tulloh R, Caputo M, Stoica S, Kia M, Parry AJ. Does the persistence of pulsatile antegrade pulmonary blood flow following bidirectional Glenn procedure affect long term outcome? Eur J Cardiothorac Surg. 2015; 47: 154-158.
12. Kalia K, Walker-Smith P, Ordoñez MV, Barlatay FG, Chen Q, Weaver H, et al. Does maintenance of pulmonary blood flow pulsatility at the time of the fontan operation improve hemodynamic outcome in functionally univentricular hearts? Pediatr Cardiol. 2021; 42: 1180-1189.
13. Olofsson P, Laurini RN, Marsál K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol. 1993; 49: 161-168.
14. Rimoy GH, Bhaskar NK, Rubin PC. Reproducibility of doppler blood flow velocity waveform measurements: Study on variability within and between day and during haemodynamic intervention in normal subjects. Eur J Clin Pharmacol. 1991; 41: 125-129.
15. Jin SM, Noh CI, Bae EJ, Choi JY, Yun YS. Impaired vascular function in patients with fontan circulation. Int J Cardiol. 2007; 120: 221-226.
16. Hendrickson RJ, Cappadona C, Yankah EN, Sitzmann JV, Cahill PA, Redmond EM. Sustained pulsatile flow regulates endothelial nitric oxide synthase and cyclooxygenase expression in co-cultured vascular endothelial and smooth muscle cells. J Mol Cell Cardiol. 1999; 31: 619-629.
17. Yin Z, Wang Z, Zhu H, Zhang R, Wang H, Li X. Experimental study of effect of fontan circuit on pulmonary microcirculation. Asian Cardiovasc Thorac Ann. 2006; 14: 183-188.
18. Henaine R, Vergnat M, Bacha EA, Baudet B, Lambert V, Belli E, et al. Effects of lack of pulsatility on pulmonary endothelial function in the Fontan circulation. J Thorac Cardiovasc Surg. 2013; 146: 522-529.
19. Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR, et al. Hemodynamics of fontan failure: The role of pulmonary vascular disease. Circ Heart Fail. 2017; 10: e004515.
20. Zhang T, Shi Y, Wu K, Hua Z, Li S, Hu S, et al. Uncontrolled antegrade pulmonary blood flow and delayed fontan completion after the bidirectional glenn procedure:real-world outcomes in china. Ann Thorac Surg. 2016; 101: 1530-1538.